Biotech IPOs in 2026: A $3.3 Billion Capital Wave Gives Drug Discovery a Bigger Stage -( $AGMD $APMD $AVLN $BRVE $CTY $GENB $IBB $KARD $PLLS $REGN $SPTX $XBI ) by John F. Heerdink, Jr. 31 minutes ago Read more Oura’s $625 Million Counsel Health Deal Puts a Bigger Healthcare Business Within Reach -( $DGX $DXCM $OURA ) by John F. Heerdink, Jr. 2 days ago Read more Serina Therapeutics’ Serves Third Quarter Update: Parkinson’s Program Gains Momentum, Setting Up a Pivotal 2027 Readout -( $PFE $SER ) by John F. Heerdink, Jr. 3 days ago Read more Mentari Therapeutics: A $490 Million Launchpad for Migraine’s Next Act -( $MTRI ) by John F. Heerdink, Jr. 3 days ago Read more Serina Therapeutics’ Parkinson’s Opportunity: A Proven Molecule, Smarter Delivery and an Emerging Clinical Case -( $SER $IBB $XBI ) by John F. Heerdink, Jr. 4 days ago Read more Eupraxia Pharmaceuticals’ Story Gains Weight & Attention Ahead of December EoE Data -( $EPRX $REGN $SNY $TAK ) by John F. Heerdink, Jr. 5 days ago Read more Eupraxia Wins RBC Outperform Rating and $14 Target as December EoE Catalyst Approaches -( $EPRX $REGN $SNY ) by John F. Heerdink, Jr. November 9, 2026 Read more Modular Medical: Nine in 10 Surveyed Injection Users Are Open to Simpler Insulin Delivery. Pivot Would Like a Word. -( $MODD ) by John F. Heerdink, Jr. November 9, 2026 Read more AI Gets Down to Business: DISCO, Amwell and Doximity Give Wall Street Something to Measure -( $AMWL $DOCS $LAW ) by John F. Heerdink, Jr. November 4, 2026 Read more Amwell Raises Its Outlook as the Turnaround Gets a Better Prognosis -( $AMWL ) by John F. Heerdink, Jr. November 4, 2026 Read more Read more